UPDATE: Oppenheimer Raises PT to $10 on Celldex Therapeutics on Improved Approval Outlook

Oppenheimer reiterated its Outperform rating on Celldex Therapeutics (NASDAQ: CLDX ) and raised its price target from $8 to $10. Oppenheimer noted, "Final data from the Phase IIb (EMERGE) of CDX-011 in metastatic breast cancer (BC) were presented this weekend. CDX-011 was well tolerated and the response rate in